Use of saliva-based nano-biochip tests for acute myocardial infarction at the point of care: a feasibility study.
Use of saliva-based nano-biochip tests for acute myocardial infarction at the point of care: a feasibility study.
复制标题
DOI：
10.1373/clinchem.2008.117713
复制
发表时间：
2009-08
影响因子：
9.3
通讯作者：
McDevitt JT
中科院分区：
文献类型：
--
作者：
Floriano PN;Christodoulides N;Miller CS;Ebersole JL;Spertus J;Rose BG;Kinane DF;Novak MJ;Steinhubl S;Acosta S;Mohanty S;Dharshan P;Yeh CK;Redding S;Furmaga W;McDevitt JT
对于患有胸痛的成人，可以使用心电图（ECG）和血清生物标志物测量来筛查和诊断心肌坏死。这些测量需要时间，可能会延误治疗并影响预后。我们的目的是研究唾液作为替代诊断液来识别急性心肌梗死 (AMI) 生物标志物的可行性和实用性。我们使用 Luminex 和芯片实验室方法检测了 41 名胸痛发作 48 小时内的 AMI 患者和 43 名表面健康对照者的血清和未刺激的全唾液中的 21 种蛋白质。通过使用逻辑回归和曲线下面积 (AUC) 进行 ROC 分析来分析数据，以评估每种生物标志物或生物标志物组合在 AMI 筛查中的诊断效用。已建立的和新型的心脏生物标志物均显示出 AMI 患者与无 AMI 对照之间的浓度存在显着差异。基于唾液的 C 反应蛋白、肌红蛋白和髓过氧化物酶生物标志物组表现出显着的诊断能力（AUC = 0.85，P < 0.0001），并且与心电图结合使用，可产生与该组（脑钠尿肽、肌钙蛋白-I、肌酸激酶-MB、肌红蛋白）相当的 AMI 强大筛查能力（AUC = 0.96）；AUC = 0.98），远远超过单独心电图的筛查能力（AUC约0.6）。在将这些发现转化为临床实践的过程中，我们将这些无刺激的全唾液测试改编为新型芯片实验室平台，用于 AMI 的原理验证筛选。作为心电图的补充，芯片实验室系统中基于唾液的测试可以为 AMI 患者院前阶段的心脏事件提供一种方便、快速的筛查方法。
For adults with chest pain, the electrocardiogram (ECG) and measures of serum biomarkers are used to screen and diagnose myocardial necrosis. These measurements require time that can delay therapy and affect prognosis. Our objective was to investigate the feasibility and utility of saliva as an alternative diagnostic fluid for identifying biomarkers of acute myocardial infarction (AMI). We used Luminex and lab-on-a-chip methods to assay 21 proteins in serum and unstimulated whole saliva procured from 41 AMI patients within 48 h of chest pain onset and from 43 apparently healthy controls. Data were analyzed by use of logistic regression and area under curve (AUC) for ROC analysis to evaluate the diagnostic utility of each biomarker, or combinations of biomarkers, in screening for AMI. Both established and novel cardiac biomarkers demonstrated significant differences in concentrations between patients with AMI and controls without AMI. The saliva-based biomarker panel of C-reactive protein, myoglobin, and myeloperoxidase exhibited significant diagnostic capability (AUC = 0.85, P < 0.0001) and in conjunction with ECG yielded strong screening capacity for AMI (AUC = 0.96) comparable to that of the panel (brain natriuretic peptide, troponin-I, creatine kinase-MB, myoglobin; AUC = 0.98) and far exceeded the screening capacity of ECG alone (AUC approximately 0.6). En route to translating these findings to clinical practice, we adapted these unstimulated whole saliva tests to a novel lab-on-a-chip platform for proof-of-principle screens for AMI. Complementary to ECG, saliva-based tests within lab-on-a-chip systems may provide a convenient and rapid screening method for cardiac events in prehospital stages for AMI patients.
登录
查看更多内容
影响因子：
37.8
作者：
Baldus, S;Heeschen, C;Hamm, CW
通讯作者：
Hamm, CW
影响因子：
6.8
作者：
Di Serio, Francesca;Lovero, Roberto;Pansini, Nicola
通讯作者：
Pansini, Nicola
DOI：
10.14219/jada.archive.1993.0007
发表时间：
1993-01-01
影响因子：
3.9
作者：
MANDEL, ID
通讯作者：
MANDEL, ID
影响因子：
9.3
作者：
Apple, FS;Murakami, MM;Herzog, CA
通讯作者：
Herzog, CA
影响因子：
9.3
作者：
Christodoulides, N;Floriano, PN;McDevitt, JT
通讯作者：
McDevitt, JT